Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Research on the Efficacy of Bosinji on Herniated Intervertebral Disc of Lumbar Spine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03386149
Recruitment Status : Completed
First Posted : December 29, 2017
Last Update Posted : February 5, 2020
Sponsor:
Collaborators:
Kyung Hee University Hospital at Gangdong
DongGuk University
Daegu Korean Medicine Hospital of Daegu Haany University
Information provided by (Responsible Party):
Byung-Kwan Seo, Kyunghee University Medical Center

Brief Summary:
This randomized controlled clinical trial is designed to evaluate the efficacy and safety of Bosinji on low back pain and radiating pain of lumbar herniated intervertebral disc (L-HIVD) by assessing pain, function, and quality of life.

Condition or disease Intervention/treatment Phase
Lumbar Disc Herniation Drug: Bosinji Drug: Loxonine tab. Procedure: Acupuncture Phase 3

Detailed Description:
Seventy-four patients between the ages of 19 and 70 with L-HIVD will be recruited by eligibility criteria and randomly allocated to the experimental group and the control group. In the experimental group, 2.5g of Bosinji granule (Tsumura & Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered in the same usage and period with the experimental group. In addition, both group will receive the same acupuncture treatment on 20 acupoints once a week for 6 weeks. 100 mm visual analogue scale (VAS) for low back pain will be assessed as a primary outcome at baseline and treatment end. Also, 100mm VAS for radiating pain, Oswestry disability index (ODI), Rolland Morris disability questionnaire (RMDQ), EQ-5D-5L and global perceived effect (GPE), Deficiency Syndrome of Kidney Index (DSKI) will be measured as secondary outcomes at baseline, 3 weeks after screening, treatment end (6 weeks, primary endpoint) and follow-up sessions (10 weeks).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Research on the Efficacy and Safety of Bosinji on LBP and Radiculopathy by HIVD of L-spine; A Multicenter, Randomized, Controlled, Clinical Trial
Actual Study Start Date : December 28, 2017
Actual Primary Completion Date : December 27, 2019
Actual Study Completion Date : January 22, 2020

Arm Intervention/treatment
Experimental: Experimental Group
In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
Drug: Bosinji

Product name : Bosinji Granule Manufacturer : Tsumura & Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)

Bosinji extract is composed of following proportion of ingredient

  • Rehmannia Root 1.7g
  • Achyranthes Root 1.0g
  • Cornus Fruit 1.0g
  • Dioscorea Rhizome 1.0g
  • Psyllium Husk 1.0g
  • Alisma Rhizome 1.0g
  • Hoelen 1.0g
  • Moutan Root Bark 1.0g
  • Cinnamon Bark 0.3g
  • Pulvis Aconiti Tuberis Purificatum 0.3g
Other Name: Ucha-Shinki-Hwan

Procedure: Acupuncture

Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.

  1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)
  2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)
  3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)

Active Comparator: Control Group
In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
Drug: Loxonine tab.
Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)
Other Name: Loxoprofen

Procedure: Acupuncture

Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.

  1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)
  2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)
  3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)




Primary Outcome Measures :
  1. Change from Baseline 100mm Pain Visual Analogue Scale (VAS) for low back pain at Week 6 [ Time Frame: Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U) ]
    Measurement instrument for subjective pain


Secondary Outcome Measures :
  1. 100mm Pain Visual Analogue Scale (VAS) for radiating pain [ Time Frame: Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U) ]
    Measurement instrument for subjective pain

  2. Oswestry Disability Index (ODI) [ Time Frame: Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U) ]
    Validated questionnaire for disability of low back pain

  3. EuroQol-5 dimensions-5 level (EQ-5D-5L) [ Time Frame: Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U) ]
    Standardized instrument for generic health status

  4. Roland-Morris Disability Questionnaire (RMDQ) [ Time Frame: Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U) ]
    Health status measure for low back pain

  5. Global Perceived Effect (GPE) [ Time Frame: Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U) ]
    Assessment of change in the patient's chief complaint

  6. Deficiency Syndrome of Kidney Index (DSKI) [ Time Frame: Week 0 (Baseline), Week 6 (Primary end point, Treatment end) ]
    Questionnaire for assessing symptoms related to deficiency syndrome of kidney



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women aged over 19 years
  2. Radiating pain matched with severer abnormality than bulging shown by CT or MRI on lumbar spine
  3. low back pain between 40 and 80 point on 100mm pain visual analogue scale
  4. Volunteers who agree to participate and sign the Informed Consent Form, following a detailedexplanation of clinical trials

Exclusion Criteria:

  1. Congenital abnormalities or surgical history on lumbar regions
  2. Red flag signs that may be suspected of cauda equina syndrome, such as bladder and bowel dysfunction or saddle anesthesia
  3. Tumor, fracture or infection in lumbar regions
  4. Injection treatment on lumbar regions within 1 week
  5. Psychiatric disorder currently undergoing treatment such as depression or schizophrenia
  6. Liver function abnormality (AST or ALT over 2times normal range)
  7. Renal fuction abnormaility (Serum creatinine > 2.0㎎/㎗)
  8. Other diseases that could affect or interfere with therapeutic outcomes, including severe gastrointestinal disease, cardiovascular disease, hypertension, diabetes, renal disease, liver disease or thyroid disorder
  9. Contraindication of NSAIDs including intercurrent disease, hypersensitivity reaction or other medication
  10. Inappropriate condition for acupuncture due to skin disease or hemostatic disorder (PT INR > 2.0 or taking anticoagulant)
  11. Women who is pregnant, breastfeeding or having pregnancy plan
  12. Other inappropriate condition for herbal medicine treatment
  13. participation in other clinical trial with 1 month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03386149


Locations
Layout table for location information
Korea, Republic of
Dongguk University Bundang Oriental Hospital
Seongnam, Gyeonggi, Korea, Republic of, 13601
Daegu Korean Medicine Hospital of Daegu Haany University
Daegu, Korea, Republic of, 42158
Kyunghee University Medical Center
Seoul, Korea, Republic of, 02447
Kyung Hee University Hospital at Gangdong
Seoul, Korea, Republic of, 05278
Sponsors and Collaborators
Kyunghee University Medical Center
Kyung Hee University Hospital at Gangdong
DongGuk University
Daegu Korean Medicine Hospital of Daegu Haany University
Investigators
Layout table for investigator information
Principal Investigator: Byung-Kwan Seo, PhD., KMD Kyunghee University Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Byung-Kwan Seo, Principal Investigator, Kyunghee University Medical Center
ClinicalTrials.gov Identifier: NCT03386149    
Other Study ID Numbers: KHNMCOH 2017-08-002
First Posted: December 29, 2017    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Byung-Kwan Seo, Kyunghee University Medical Center:
Herniated Intervertebral Disc of Lumbar Spine
Low Back Pain
Radiculopathy
Bosinji
Herbal Medicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Radiculopathy
Hernia
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Pathological Conditions, Anatomical
Loxoprofen
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents